Hyloris Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Hyloris Pharmaceuticals has a total shareholder equity of €34.7M and total debt of €120.0K, which brings its debt-to-equity ratio to 0.3%. Its total assets and total liabilities are €45.4M and €10.8M respectively.
Key information
0.3%
Debt to equity ratio
€120.00k
Debt
| Interest coverage ratio | n/a |
| Cash | €27.96m |
| Equity | €34.66m |
| Total liabilities | €10.78m |
| Total assets | €45.44m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 52U's short term assets (€32.8M) exceed its short term liabilities (€8.8M).
Long Term Liabilities: 52U's short term assets (€32.8M) exceed its long term liabilities (€1.9M).
Debt to Equity History and Analysis
Debt Level: 52U has more cash than its total debt.
Reducing Debt: 52U had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 52U has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 52U has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 17.3% each year.